Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVEMOM-HT Cream
- Development stage
- Unknown
- Lead developer
- Avancer Labs
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
AVEMOM-HT Cream is a topical fixed-dose combination cream developed and manufactured by Avancer Labs. It contains three active ingredients: hydroquinone (4% w/w), mometasone furoate (0.1% w/w), and tretinoin (0.025% w/w). Hydroquinone is a skin-lightening agent that inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis, thereby reducing skin pigmentation. Mometasone furoate is a medium-potency synthetic corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by activating glucocorticoid receptors. Tretinoin is a retinoid that binds to retinoic acid receptors to promote epidermal cell turnover and facilitate the dispersion of existing melanin. AVEMOM-HT Cream is primarily indicated for the short-term treatment of moderate-to-severe melasma and related hyperpigmentation disorders of the face.
- Brand names
- AVEMOM-HT Cream
- Other names
- hydroquinone + mometasone + tretinoinhydroquinone + mometasone furoate + tretinoin
02
Targets
GR (Glucocorticoid receptor)RARA (Retinoic acid receptor alpha)RARB (Retinoic acid receptor beta)RARG (Retinoic acid receptor gamma)TYR (Tyrosinase)
Beyond the preview
Go deeper on AVEMOM-HT Cream.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVEMOM-HT Cream.